scholarly journals Case Report of Diffuse Large B Cell Lymphoma of Uterine Cervix Treated at a Semiurban Cancer Centre in North India

2016 ◽  
Vol 2016 ◽  
pp. 1-4
Author(s):  
Vibhor Sharma ◽  
Tapas Dora ◽  
Mehul Patel ◽  
Sankalp Sancheti ◽  
Epari Sridhar
Keyword(s):  
B Cell ◽  
Uterine Cervix ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
North India ◽  
Intrathecal Methotrexate ◽  
Cancer Centre ◽  
Large B Cell Lymphoma ◽  
Response To Chemotherapy ◽  
Large B Cell

Lymphoma of the uterine cervix is very rare. We report a case of diffuse large B cell lymphoma (DLBCL) involving the uterine cervix treated at a newly commissioned semiurban cancer centre in north India in 2015. Data for this study was obtained from the hospital electronic medical records and the patient’s case file. We also reviewed published case reports of uterine and cervical lymphoma involving forty-one patients. We treated a case of stage IV DLBCL cervix with six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) and intrathecal methotrexate followed by consolidation with radiotherapy. The patient showed complete response to chemotherapy. We conclude that, in advanced stage lymphoma involving uterus and cervix, combination of chemotherapy and radiotherapy is effective in short term.

scholarly journals Lactic acidosis: a unique presentation of diffuse large B-cell lymphoma

2019 ◽  
Vol 12 (10) ◽  
pp. e230277 ◽  
Author(s):  
Turab Jawaid Mohammed ◽  
Rohit Gosain ◽  
Rajeev Sharma ◽  
Pallawi Torka
Keyword(s):  
Lactic Acidosis ◽  
B Cell ◽  
Cell Lymphoma ◽  
Performance Status ◽  
B Cell Lymphoma ◽  
Intrathecal Methotrexate ◽  
Dramatic Improvement ◽  
Metabolic Encephalopathy ◽  
Large B Cell Lymphoma ◽  
Large B Cell

An elderly man in the seventh decade of life was brought to the hospital with worsening mental status. Blood tests revealed anaemia and thrombocytopenia with elevated lactate dehydrogenase and serum lactate levels. CT scan showed bulky thoracic and abdominal lymphadenopathy with splenomegaly. A positron emission tomography scan confirmed the above and in addition, revealed bilateral adrenal involvement. Bone marrow biopsy revealed non-germinal centre B-cell-like (non-GCB)-diffuse large B-cell lymphoma (DLBCL). Prompt treatment with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab with intrathecal methotrexate chemotherapy resulted in a dramatic improvement in the patient’s condition. This vignette serves as a reminder to include aggressive lymphomas like DLBCL in the differential diagnoses of patients presenting with metabolic encephalopathy and lactic acidosis. Our patient was moribund at presentation with poor sensorium and failure to thrive. The dilemma was whether to take an aggressive stand and start chemotherapy urgently or whether to stabilise the patient first and then consider the treatment of DLBCL. We make a case for initiating therapy promptly in such patients irrespective of their performance status.

scholarly journals Intravascular Large B-Cell Lymphoma Presenting as Acute Axonal Polyneuropathy: A Case Report and Literature Review

2020 ◽  
Vol 8 ◽  
pp. 232470962095999
Author(s):  
Jordan M. Minish ◽  
Amar H. Kelkar ◽  
Amol R. Mehta ◽  
Maira Gaffar ◽  
Nam H. Dang
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
Disease Process ◽  
B Cell Lymphoma ◽  
Intrathecal Methotrexate ◽  
Common Disease ◽  
Success Rates ◽  
Large B Cell Lymphoma ◽  
Axonal Polyneuropathy ◽  
Large B Cell

Intravascular large B-cell lymphoma (ILBL) is a rare and difficult to diagnose subtype of large B-cell lymphoma. The most common locations of presentation are in the central nervous system and the skin, but there are reports of other organ involvement. Due to the indolence, nonspecific symptoms, and rarity of the disease, this form of lymphoma is most often diagnosed postmortem. In this article, we describe a case of ILBL that presented as a rapidly progressive acute axonal polyneuropathy. Acute axonal polyneuropathy is a common disease process with a wide differential diagnosis, but there is limited literature on its prevalence as the presenting symptom of ILBL. This patient was treated with R-EPOCH and intrathecal methotrexate with significant improvement in his polyneuropathy after 1 cycle, and complete remission after 6 cycles. Data on chemotherapy regimens and their success rates for this disease are lacking.

Diffuse large B-cell lymphoma: experience from a tertiary care center in north India

2009 ◽  
Vol 27 (2) ◽  
pp. 310-318 ◽  
Author(s):  
Rohan Khera ◽  
Snigdha Jain ◽  
Lalit Kumar ◽  
S. Thulkar ◽  
M. Vijayraghwan ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
Care Center ◽  
Tertiary Care ◽  
B Cell Lymphoma ◽  
North India ◽  
Tertiary Care Center ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals The Role of Consolidative Radiotherapy after a Complete Response to Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma in the Rituximab Era: Results from a Systematic Review with a Meta-Analysis

2015 ◽  
Vol 134 (2) ◽  
pp. 111-118 ◽  
Author(s):  
Chunhong Hu ◽  
Chao Deng ◽  
Wen Zou ◽  
Guangsen Zhang ◽  
Jingjing Wang
Keyword(s):  
Systematic Review ◽  
B Cell ◽  
Cell Lymphoma ◽  
Meta Analysis ◽  
B Cell Lymphoma ◽  
Complete Response ◽  
Large B Cell Lymphoma ◽  
Response To Chemotherapy ◽  
Large B Cell

Background: The current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP). The role of radiotherapy (RT) after complete response (CR) to RCHOP in patients with DLBCL remains unclear. This systematic review with a meta-analysis is an attempt to evaluate this role. Methods: Studies that evaluated RT versus no-RT after CR to RCHOP for DLBCL patients were searched in databases. Hazard ratios (HR) with their respective 95% confidence intervals (CI) were calculated using a random-effects model. Results: A total of 4 qualified retrospective studies (633 patients) were included in this review. The results suggested that RT improved overall survival (OS; HR 0.33, 95% CI 0.14-0.77) and progression-free/event-free survival (PFS/EFS; HR 0.24, 95% CI 0.11-0.50) in all patients compared with no-RT. In a subgroup analysis of patients with stage III-IV DLBCL, RT improved PFS/EFS (HR 0.19, 95% CI 0.07-0.51) and local control (HR 0.12, 95% CI 0.03-0.44), with a trend of improving OS (HR 0.35, 95% CI 0.12-1.05). Conclusion: Consolidation RT could significantly improve outcomes of DLBCL patients who achieved a CR to RCHOP. However, the significance of these results was limited by these retrospective data. Further investigation of the role of consolidation RT in the rituximab era is needed.

scholarly journals Primary Large B Cell Lymphoma of the Cervix: A Case Report and review of literature

2021 ◽  
Author(s):  
Soheila Aminimoghaddam ◽  
Elnaz Salarifar ◽  
Somayyeh Noei Teymoordash
Keyword(s):  
B Cell ◽  
Uterine Cervix ◽  
Cell Lymphoma ◽  
Abnormal Uterine Bleeding ◽  
B Cell Lymphoma ◽  
Review Of Literature ◽  
Large B Cell Lymphoma ◽  
Reproductive Aged Women ◽  
Large B Cell ◽  
Postcoital Bleeding

Abstract The primary diffuse large B cell lymphoma (DLBCL) of the uterine cervix is extremely rare. In the present study, we described two cases of DLBCL of the uterine cervix in reproductive-aged women complaining of postcoital bleeding, recurrent vaginal discharge, and abnormal uterine bleeding.

scholarly journals Aggressive CD5-Positive Primary Bone Marrow Diffuse Large B-Cell Lymphoma with Leukemic Presentation

2021 ◽  
Vol 2021 ◽  
pp. 1-3
Author(s):  
Mark G. Evans ◽  
Sherif A. Rezk ◽  
Lauren C. Pinter-Brown ◽  
Xiaohui Zhao
Keyword(s):  
Bone Marrow ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Intrathecal Methotrexate ◽  
Non Hodgkin Lymphoma ◽  
Large B Cell Lymphoma ◽  
Primary Bone ◽  
Primary Bone Marrow ◽  
Large B Cell

Primary bone marrow diffuse large B-cell lymphoma is an exceedingly rare form of non-Hodgkin lymphoma. It may demonstrate a leukemic presentation, and a proportion of cases have CD5 expression. The prognostic implications of this CD5-positivity remain unknown. Here, we present a 78-year-old man who presented with circulating peripheral blood lymphoma cells and a hypercellular marrow involved by diffuse large B-cell lymphoma, germinal center B-cell subtype. The patient responded favorably to six cycles of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) and intrathecal methotrexate. He unfortunately relapsed in several enlarged inguinal lymph nodes and succumbed to the lymphoma approximately one year after diagnosis, demonstrating the particularly aggressive clinical course of his disease.

scholarly journals Effect of unintentional cyclophosphamide underdosing on diffuse large B-cell lymphoma response to chemotherapy: a retrospective review

CMAJ Open ◽  
2016 ◽  
Vol 4 (2) ◽  
pp. E236-E239
Author(s):  
M. Al-Ahmadi ◽  
A. Lazo-Langner ◽  
J. Mangel ◽  
A. D. B. Phm ◽  
K. Liu ◽  
...  
Keyword(s):  
B Cell ◽  
Retrospective Review ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Response To Chemotherapy ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document